Pembrolizumab as first-line therapy in programmed death ligand 1–positive advanced lung cancer

Is it as effective as we think it is?

Daniel A. Goldstein, Usama Bilal, Vinay Prasad

Research output: Contribution to journalComment/debate

3 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)3872-3874
Number of pages3
JournalCancer
Volume123
Issue number20
DOIs
StatePublished - Oct 15 2017

Fingerprint

Lung Neoplasms
Ligands
Therapeutics
pembrolizumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pembrolizumab as first-line therapy in programmed death ligand 1–positive advanced lung cancer : Is it as effective as we think it is? / Goldstein, Daniel A.; Bilal, Usama; Prasad, Vinay.

In: Cancer, Vol. 123, No. 20, 15.10.2017, p. 3872-3874.

Research output: Contribution to journalComment/debate

@article{1b723f1be18d40ba996bcb51c9aaa4d8,
title = "Pembrolizumab as first-line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is?",
author = "Goldstein, {Daniel A.} and Usama Bilal and Vinay Prasad",
year = "2017",
month = "10",
day = "15",
doi = "10.1002/cncr.30868",
language = "English (US)",
volume = "123",
pages = "3872--3874",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "20",

}

TY - JOUR

T1 - Pembrolizumab as first-line therapy in programmed death ligand 1–positive advanced lung cancer

T2 - Is it as effective as we think it is?

AU - Goldstein, Daniel A.

AU - Bilal, Usama

AU - Prasad, Vinay

PY - 2017/10/15

Y1 - 2017/10/15

UR - http://www.scopus.com/inward/record.url?scp=85021420362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021420362&partnerID=8YFLogxK

U2 - 10.1002/cncr.30868

DO - 10.1002/cncr.30868

M3 - Comment/debate

VL - 123

SP - 3872

EP - 3874

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 20

ER -